Jade Biosciences Q2 FY26 net loss widens to $55.8 million

Reuters2026/08/10 11:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Jade Biosciences posted a Q2 net loss of $55.8 million, widening from $32.1 million a year earlier.
R&D expense climbed 122.1% year over year to $50.1 million; G&A rose 71.2% to $8.9 million.
Cash, cash equivalents, and investments totaled $461.2 million at June 30, with runway expected into Q4 2028.
JADE101 interim Phase 1 data showed about 70% mean IgA reductions after a single 700 mg dose; Phase 2 interim data expected in 2027.
Phase 3 for JADE101 is expected to start in H1 2027; JADE301 Phase 1 is slated for Q4 2026, with interim data in H2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100700PRIMZONEFULLFEED9806227) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Jade Biosciences Q2 FY26 net loss widens to $55.8 million

You may also like

Crypto prices